BioMS Medical Corp.
TSX : MS

BioMS Medical Corp.

August 24, 2005 08:30 ET

Webcast Alert: BioMS Medical Corp. Presentation at Informed Investors Biotechnology, Healthcare, Pharmaceuticals Investor Forum to be Webcast on Thursday, August 25, 2005, 11:00 am ET

EDMONTON, ALBERTA--(CCNMatthews - Aug. 24, 2005) - BioMS Medical Corp. (TSX:MS) will present at the following forum:



What: BioMS Medical Corp. (TSX:MS) will give a presentation at
Informed Investors Biotechnology, Healthcare, Pharmaceuticals On-line
Investors Forum.

The keynote presentation will be from Dr. Adam K. Noah, Research
Analyst with Granite Financial Group

When: August 25, 2005 @11:00 AM Eastern Time

Where: www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=89493

How: Live over the Internet-Simply log on to the web at the address
above.


Contact: Amanda Stadel, Investor Relations Manager, astadel@biomsmedical.com , (780)413-7152

If you are unable to attend the live event, the forum will be archived and available via the Informed Investors website at www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=89493

BioMS Medical Corp. is a biotechnology company dedicated to the development and commercialization of innovative therapies. The company is focused on three novel therapeutic technologies, all of which have been licensed from the University of Alberta.

BioMS Medical's lead product, MBP8298, is a promising treatment for multiple sclerosis (MS). With over 2.5 million MS patients worldwide, MBP8298 has the potential to positively affect hundreds of thousands of lives. MBP8298 is currently in a pivotal Phase II/III trial for patients with secondary progressive MS (SPMS). This is the only late stage SPMS clinical trial in the world for a form of the disease for which there are few treatment options.

Additional technologies include HYC750, a potential method for the mobilization of stem cells and neutrophils for the treatment of cancer therapy related side effects, and an equity investment in BioCyDex, a private company developing a unique proprietary drug delivery technology to deliver both existing and novel anti-viral and chemotherapeutic compounds directly into cells for the purpose of improving their effectiveness.

BioMS Medical is a publicly traded company on the Toronto Stock Exchange (TSX:MS)

Contact Information